Veillonella

With Growing Global Safety Concerns Over Sleep Aids, FitBiomics Co-Authors Study Showcasing New Probiotic Alternative

Retrieved on: 
Tuesday, June 27, 2023
Sulfotransferase, Science, Human, Veillonella, Lactobacillus, Nature Medicine, Sleep, Scientific American, Physiology, Research, Inflammation, History, Doctor of Philosophy, Harvard Medical School, Defecation, Oxidative stress, The New York Times, Sleep disorder, Sleep deprivation, NPR, Health, Probiotic, Neuroscientist, Safety, Exertion, Pharmaceutical industry, Dietary supplement, Nursing, Microbiology

NEW YORK, June 27, 2023 /PRNewswire/ -- Researchers are unveiling the remarkable effects of Nella, a multi-strain probiotic consortium developed by microbiome innovation company FitBiomics, on promoting sleep quality in humans in a study released today on World Microbiome Day. With a cutting-edge, two-phase clinical approach, the study showcases Nella's broader health benefits along with its potential to transform the way we approach sleep and probiotic alternatives to sleep aids.

Key Points: 
  • With a cutting-edge, two-phase clinical approach, the study showcases Nella's broader health benefits along with its potential to transform the way we approach sleep and probiotic alternatives to sleep aids.
  • "Our study indicates that the probiotic consortium in Nella significantly enhances sleep quality which is noteworthy given the growing concerns around the use of traditional sleep aids."
  • Nella's probiotic consortium offers a safe and potentially more consistent solution to sleep-related issues compared to current sleep aids.
  • "This study marks an important milestone in our understanding of the role probiotics play in improving sleep quality and overall health.

FitBiomics to Make Fatigue Obsolete, Provides Early Access Opportunity to Lactic Acid Metabolizer, Veillonella

Retrieved on: 
Tuesday, April 18, 2023
Midnight, Mobile Suit Gundam, Nature Medicine, Engineering, Lactic acid, Research, Harvard University, Doctor of Philosophy, Harvard Fatigue Laboratory, Wyss Institute for Biologically Inspired Engineering, Wyss Institute, Longevity, Health, VIP, Fatigue, Pharmaceutical industry, Dietary supplement, Veillonella

NEW YORK, April 18, 2023 /PRNewswire/ -- FitBiomics, a leading biotechnology organization using microbiome innovation to enhance human health and performance, has announced successful translation of Veillonella. Veillonella is a first-of-its-kind, next-generation probiotic that naturally converts lactic acid into energy to fight fatigue and promote endurance. To celebrate this achievement and accelerate commercial optimization of Veillonella, FitBiomics opened applications for Project V - an early access opportunity to try Veillonella.

Key Points: 
  • Veillonella is a first-of-its-kind, next-generation probiotic that naturally converts lactic acid into energy to fight fatigue and promote endurance.
  • To celebrate this achievement and accelerate commercial optimization of Veillonella, FitBiomics opened applications for Project V - an early access opportunity to try Veillonella.
  • FitBiomics plans to bring Veillonella, a discovery first published in Nature Medicine in 2019, to market before the end of the year.
  • Veillonella, along with Nella, the initial product from FitBiomics, are patented probiotic strains that go beyond gut health and provide holistic health benefits.